Target Name: CD3G
NCBI ID: G917
Other Name(s): T3G | CD3g molecule, gamma (CD3-TCR complex) | CD3GAMMA | IMD17 | T-cell antigen receptor complex, gamma subunit of T3 | CD3g | T-cell receptor T3 gamma chain | T-cell surface glycoprotein CD3 gamma chain | CD3G_HUMAN | CD3 gamma subunit of T-cell receptor complex | CD3-GAMMA | CD3g antigen, gamma polypeptide (TiT3 complex) | CD3g molecule, epsilon (CD3-TCR complex) | CD3 gamma polypeptide

CD3G: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain can have a significant impact on an individual's quality of life, and its associated economic burden is substantial. The development of new treatments for chronic pain is crucial for improving the lives of patients. One promising drug candidate is CD3G, a potential drug target and biomarker for the treatment of chronic pain.

CD3G: The Potential Drug Target

CD3G is a protein that is expressed in various tissues and cells, including the central nervous system (CNS). It is involved in the immune response and has been implicated in the development and maintenance of chronic pain. Several studies have suggested that CD3G may be a potential drug target for the treatment of chronic pain.

CD3G's involvement in the immune response has led to the hypothesis that it may play a role in modulating pain perception. Chronic pain is often associated with an overactive immune system, which leads to the production of pro-inflammatory cytokines. These cytokines can contribute to the persistent pain associated with chronic pain conditions. By targeting CD3G, drugs may be able to reduce the production of these pro-inflammatory cytokines and alleviate pain.

Additionally, CD3G has been shown to interact with other pain modulators, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs). These interactions may make CD3G an effective treatment for chronic pain conditions that are not responding to traditional pain medications.

CD3G's potential as a drug target is further supported by its expression in the CNS, which is the primary site of pain processing. CD3G has been shown to interact with several key molecules in the CNS, including opioid receptors and neurotrophins. These interactions may enable CD3G to modulate pain processing and potentially target the underlying mechanisms of chronic pain.

CD3G as a Biomarker

CD3G may also serve as a biomarker for the evaluation of chronic pain. The development of new biomarkers for chronic pain has the potential to improve the accuracy and non-invasive nature of pain assessment. CD3G has been shown to be a potential biomarker for chronic pain in various experimental models.

CD3G has been shown to increase the expression of pain-related genes in mouse models of chronic pain. Additionally, the levels of CD3G have been shown to decrease in the spinal cords of mice with chronic pain. These findings suggest that CD3G may be a useful biomarker for the assessment of chronic pain.

CD3G's Potential Therapeutic Applications

CD3G's potential as a drug target and biomarker makes it an attractive candidate for the treatment of chronic pain. Several studies have suggested that CD3G may be effective in the treatment of various chronic pain conditions, including osteoarthritis, neuropathic pain, and chronic low back pain.

One potential mechanism of action for CD3G's treatment of chronic pain is its ability to modulate pain processing. By reducing the production of pro-inflammatory cytokines and interacting with other pain modulators, CD3G may be able to alleviate pain without the use of traditional pain medications.

Another potential mechanism of action for CD3G's treatment of chronic pain is its ability to modulate the immune system. Chronic pain is often associated with an overactive immune system, and CD3G may be able to reduce the production of pro-inflammatory cytokines and improve the immune response.

CD3G's potential as a drug target and biomarker makes it an exciting candidate for the treatment of chronic pain. Further research is needed to

Protein Name: CD3 Gamma Subunit Of T-cell Receptor Complex

Functions: Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways (PubMed:2470098). In addition to this role of signal transduction in T-cell activation, CD3G plays an essential role in the dynamic regulation of TCR expression at the cell surface (PubMed:8187769). Indeed, constitutive TCR cycling is dependent on the di-leucine-based (diL) receptor-sorting motif present in CD3G

More Common Targets

CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15